Announcements
- Addex Announces Upcoming Conferences it will participate for H1 2023
- Addex Regains Nasdaq Listing Compliance
- Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
- Addex Provides Corporate Update and Financial Guidance
- Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
- Addex Reports Q3 2022 Financial Results and Provides Corporate Update
- Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
- Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Addex Increases Issued Share Capital to Create Treasury Shares
- Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
More ▼
Key statistics
On Tuesday, Addex Therapeutics Ltd (0QNV:LSE) closed at 0.2355, 105.86% above the 52 week low of 0.1144 set on Dec 27, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.2355 |
Average volume | -- |
---|---|
Shares outstanding | 115.35m |
Free float | 70.80m |
P/E (TTM) | -- |
Market cap | 20.53m CHF |
EPS (TTM) | -0.5532 CHF |
Data delayed at least 20 minutes, as of Mar 07 2023 14:40 GMT.
More ▼